Biogen (BIIB) Gross Margin (2009 - 2026)

Biogen (BIIB) has reported Gross Margin for 18 consecutive years, with 73.32% the latest figure, recorded in Q1 2026.

• In Q1 2026, Gross Margin fell 79.0% year-over-year to 73.32%; the TTM figure through Mar 2026 stood at 75.49% (down 9.0% YoY), while the FY2025 annual figure was 75.69%, down 43.0% from the prior year.
• Gross Margin came in at 73.32% for Q1 2026 at Biogen, down from 78.26% in the prior quarter.
• The five-year high for Gross Margin was 93.55% in Q4 2022, with the low at 73.09% in Q1 2023.
• Average Gross Margin over 5 years is 78.94%, with a median of 76.33% recorded in 2024.
• Across the five-year window, Gross Margin soared 689 bps in 2022 and sank 1690 bps in 2024, its largest moves.
• Year by year, Gross Margin stood at 93.55% in 2022, then declined by 0 bps to 93.13% in 2023, then slipped by 18 bps to 76.23% in 2024, then advanced by 3 bps to 78.26% in 2025, then fell by 6 bps to 73.32% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 73.32%, 78.26%, and 73.39% for Q1 2026, Q4 2025, and Q3 2025 respectively.